Company intelligence / Profile preview
Archer Pharmaceuticals
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
Overview
Archer Pharmaceuticals specializes in drug discovery and development targeting Alzheimer's disease. Its lead compound, ARC029 (nilvadipine), was evaluated through a large European Phase III trial but did not demonstrate efficacy over placebo. The company continues to develop next-generation compounds such as ARC031 with improved safety profiles. Their approach centers on repurposing known small molecules with mechanistic rationale supported by preclinical data.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesRepurposed drugs (notably calcium channel blockers)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Archer Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Archer Pharmaceuticals.